CLYM
What one share of Climb Bio holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for patients living with immune-mediated diseases. We have built our pipeline by strategically acquiring or in-licensing product candidates that we believe have clear biological rationale, well-defined development pathways, and the potential to address multiple indications.
Climb Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.82 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.76 |
| Cash and investments | $4.17 |
| Book value | $4.17 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$10.49 | — | −$6.44 | — | −$7.31 |
| 2021 | — | −$4.24 | — | −$2.94 | — | — |
| 2022 | — | −$1.72 | — | −$1.42 | — | $4.84 |
| 2023 | — | −$1.30 | $0.00 | −$0.76 | — | $3.88 |
| 2024 | — | −$1.53 | $0.00 | −$0.32 | — | $3.15 |
| 2025 | — | −$0.88 | $0.00 | −$0.80 | — | $3.36 |